expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
Published 3 years ago • 261 plays • Length 1:39:18Download video MP4
Download video MP3
Similar videos
-
1:13:00
expanding the benefits of parp inhibitors to more patients with breast cancer and earlier settings
-
5:33
cancer immune checkpoint inhibitors
-
31:24
harnessing the immune system in the treatment of triple-negative breast cancer
-
1:04:28
harnessing the immune system in the treatment of triple-negative breast cancer
-
5:09
use of checkpoint inhibitors in breast cancer treatment
-
5:10
introduction to immune checkpoint inhibitor (ici) immunotherapy
-
44:56
immune checkpoint blockade in cancer therapy
-
26:57
immune checkpoint inhibitors (ici) - and gilvetmab - for treating dog cancer
-
51:24
her2 and her3 alterations as therapeutic targets of increasing significance in solid tumors
-
57:18
translating progress with immunotherapies and targeted agents into improved outcomes in tnbc
-
36:54
immunotherapy in advaced btc standardizing team based strategies with immune checkpoint inhibitors
-
28:45
refining the role of immune checkpoint inhibitors in endometrial cancer
-
39:06
expanding the benefits of immuno-oncology through novel rational targets and combinations
-
0:47
the role of immune checkpoint inhibitors in triple-negative breast cancer
-
1:03:55
the nuances of immunotherapy biomarker testing in solid tumors
-
1:29:06
leveraging neoadjuvant and adjuvant immunotherapy to improve outcomes in early-stage cancers
-
55:16
targeting tigit to extend immunotherapy benefits to more cancer patients
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
1:20:02
her2-low expression in breast cancer: opportunities for expanding treatment benefit to more patients
-
58:57
navigating the complexities of biomarker testing in the expanding field of precision immuno-oncology
-
1:43
the role of the checkpoint inhibitors in breast cancer
-
0:53
strategies to enhance anti-tumor t cell response to immune checkpoint inhibitors in tnbc